CANbridge to Participate in Two Investor Conferences in September

13 3 CANbridge to Participate in Two Investor Conferences in September

BEIJING and BURLINGTON, Mass., Sept. 6, 2023 /PRNewswire/ — CANbridge Pharmaceuticals Inc. (HKEX:1228), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, today announced its participation in two upcoming investor conferences.

  • Morgan Stanley 21st Annual Global Healthcare Conference
    • Date: September 13, 2023
    • Location: New York
    • Founder, Chairman & CEO James Xue, PhD, and Chief Financial Officer, Glenn Hassan will participate in a Fireside Chat on Wednesday, September 13, 2023, at 12:15 PM (EST).
  • H.C. Wainwright 25th Annual Global Investment Conference
    • Date: September 11, 2023
    • Location: New York

About CANbridge Pharmaceuticals Inc. 

CANbridge Pharmaceuticals Inc. (HKEX:1228) is a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies for rare disease and rare oncology. CANbridge has a differentiated drug portfolio, with 4 approved drugs and a pipeline of 10 assets, targeting prevalent rare disease and rare oncology indications that have unmet needs and significant market potential. These include Hunter syndrome and other lysosomal storage disorders, complement-mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases, as well as glioblastoma multiforme. The CANbridge Next-Generation Innovation and Process Development Facility is developing novel, potentially curative, gene therapies for rare genetic diseases, including Pompe disease, Fabry disease, spinal muscular atrophy (SMA) and other neuromuscular conditions, and collaborates with world-leading researchers and biotech companies. Animal data from the SMA gene therapy was presented in 2022 at the American Society for Gene and Cell Therapy (ASGCT), the European Society for Gene and Cell Therapy (ESGCT) and the World Muscle Congress. CANbridge global partners include: Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, UMass Chan Medical School, the University of Washington School of Medicine and Scriptr Global.

For more on CANbridge Pharmaceuticals Inc., please go to: www.canbridgepharma.com.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the data on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

Cision View original content:https://www.prnewswire.com/news-releases/canbridge-to-participate-in-two-investor-conferences-in-september-301918869.html

SOURCE CANbridge Pharmaceuticals, Inc.

rt CANbridge to Participate in Two Investor Conferences in September

Featured image: DepositPhotos © Belchonock

Disclaimer